Alerts will be sent to your verified email
Verify Email
COLINZ
|
Colinz Laboratories
|
Parmax Pharma
|
Beryl Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
4.05 % | -1624.87 % | 2.54 % |
|
5yr average Equity Multiplier
|
1.3 | 46.04 | 2.23 |
|
5yr Average Asset Turnover Ratio
|
0.7 | 0.95 | 1.08 |
|
5yr Avg Net Profit Margin
|
4.66 % | -9.48 % | 0.66 % |
|
Price to Book
|
1.16 | 0.0 | 1.16 |
|
P/E
|
22.81 | 0.0 | 49.26 |
|
5yr Avg Cash Conversion Cycle
|
-0.66 Days | -161.05 Days | -619.24 Days |
|
Inventory Days
|
64.79 Days | 73.65 Days | 36.1 Days |
|
Days Receivable
|
51.75 Days | 40.27 Days | 98.89 Days |
|
Days Payable
|
78.66 Days | 328.05 Days | 969.29 Days |
|
5yr Average Interest Coverage Ratio
|
9.16 | 1.16 | 1.68 |
|
5yr Avg ROCE
|
6.01 % | -9.94 % | 5.73 % |
|
5yr Avg Operating Profit Margin
|
6.82 % | 3.93 % | 7.19 % |
|
5 yr average Debt to Equity
|
0.07 | 17.42 | 0.64 |
|
5yr CAGR Net Profit
|
30.39 % | n/a | 72.78 % |
|
5yr Average Return on Assets
|
3.14 % | -6.43 % | 1.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.0 % | 30.8 % | 26.38 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.01 % | 0.0 | 1.46 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Colinz Laboratories
|
Parmax Pharma
|
Beryl Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|